Filing Flows › Industries › Medicinal Chemicals & Botanical Products › Capital spending and supply chain
Medicinal Chemicals & Botanical Products: capital spending and supply chain
SIC 2833 · 13 companies with filed cash-flow statements
Analysis
13 companies in Medicinal Chemicals & Botanical Products (SIC 2833) spent $200M on capital projects over their latest twelve months, 42% of the $473M their operations generated; the three largest spenders — CURLF, TRLV, AAWH — account for 72%.
Capital spending is 3.9% of the industry's $5.1B of annual revenue.
By the industry's asset mix most of it goes to equipment (44%); about $20.6M is imported.
The largest supplier of that spending is manufacturing structures ($34.2M).
Its largest supplying industries, by the input-output tables: imports ($722M), drugs and druggists' sundries ($482M), biological product (except diagnostic) manufacturing ($360M).
Charts
Capital spending by company
| Company | Capital spending | Operating cash flow | Capex / OCF | Period |
|---|---|---|---|---|
| CURLF Curaleaf Holdings | $66.5M | $114M | 58% | TTM to Q3 2026 |
| TRLV Trulieve Cannabis | $54.3M | $242M | 22% | TTM to Q3 2026 |
| AAWH Ascend Wellness Holdings | $24.3M | $17.4M | 140% | TTM to Q2 2026 |
| CRON Cronos Group | $15.7M | $81.1M | 19% | TTM to Q3 2026 |
| JUSH Jushi Holdings | $12.9M | $19.0M | 68% | TTM to Q3 2026 |
| USNA Usana Health Sciences | $11.8M | $27.7M | 43% | TTM to Q2 2026 |
| CGC Canopy Growth | $6.5M | −$73.1M | — | TTM to Q2 FY27 |
| BTMD biote | $4.5M | $24.4M | 18% | TTM to Q2 2026 |
| LEEEF Leef Brands | $1.8M | −$2.0M | — | TTM to Q2 2026 |
| MRMD Marimed | $1.3M | $9.3M | 14% | TTM to Q2 2026 |
| MTEX Mannatech | $861K | $2.5M | 35% | TTM to Q2 2026 |
| FTLF Fitlife Brands | $13K | $10.0M | 0% | TTM to Q2 2026 |
| ADIA Adia Med | $5K | −$176K | — | TTM to Q2 2026 |
The interactive money flow: switch views, follow each dollar →
Evidence grades: A filed figure · B computed from filed figures · C industry average (BEA input-output and fixed-asset tables) applied to filed figures. Estimates are not the companies’ own records. Not investment advice.